Main > > >ATRIAL FIBRILLATION (AFi). *
Cardio.>Arrhytmia. Atrial Fibrillation Diag.: AI (Artificial Intelligence) Enabled Platform.
USA Launch Date: 2017. 03.16.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2019. 07.04.
Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: AI (Artificial Intelligen- ce) (1)+ECG (Electro CardioGram)+Digital
Stethoscope (2)
(1) USA Clearance Date: 2020. 01.28.
(*) Company; Patent (2); & Web-Sites
Acailable on Request.
UpDate: 2020. 02.04.
Cardio.>Arrhytmia. Atrial Fibrillation Diag.: Cloud- & AI (Artifi- cial Intelligence)-Powered ECG (Electro
Cardio Gram) Analysis.
EU Approval Date : ?
USA Approval Date: 2017. 07.05.
(*) Company; Patent & Product Web-
Site Available on Request.
UpDate: 2019. 02.25.
Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: ECG Personal (Mobile) Single Lead.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.
Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: High Resolution (HR) Imaging & Non-Contact Mapping System.
Detects & Displays both Standard Volta-
ge-based & HR "Dipole Density (Charge-
Source) Maps". The System uniquely com-
bines "UltraSound (US) Anatomy Construc-
tion" with ability to map the "Electri-
cal-Conduction" of each "HeartBeat" to
Identify Complex Arrhytmias across the
entire "Atrial Chamber". Following each Ablation Treat. the Heart can be "Re-
Mapped" in seconds to continually Visua-
lize any changes from the prior Mapping.
Individualized & Personalized Catheter
Ablation.
IntraCardiac Echocardiography (ICE) &
ElectroAnatomic Mapping Systems.
System ACQuires up to 115,000 Ultra-
Sound (US) Data Points/Minute to rapidly
create an Anatomic Reconstruction of a
chamber of heart & up to 150,000 Biopo-
tential samples/Second to create a 3D
map of cardiac electrical activity of whole chamber in real-time.
System allows ElectroPhysiologists to
tailor TREATs. for each individual pa-
tient & then adapt that TREAT. Iterati-
vely-on the fly-while the patient is
still in ElectroPhysiology (EP) lab.
With System, Physicians can create a
full-chamber, 360-Degree Look at the
Atrium in Real-Time for each individual
patient enabling truly customized TREAT.
for every case using an iterative map,
ablate, re-map, ablate strategy.
EU Approval Date : 2016. 05.04.
USA Approval Date: 2017. 10.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.26.
Cardio.>Arrhytmia. Atrial Fibrillation.
Mapping. AI-Enabled Electrographic Flow
(Analyze and Visualize the Flow of Action Potentials)
EU Approval Year: 2018.
(*) Company; Patents & Web-Site Avai-
Lable on Request.
UpDate: 2019. 07.04.
Cardio.>Arrhytmia. Atrial Fibrillation Mapping. Cardiac System.
USA Launch Date: 2017. 01.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.01.
Cardio.>Arrhytmia. Atrial Fibrillation Mapping. HD Grid Catheter SE (Sensor Enabled).
EU Approval Date : 2017. 12.
USA Approval Date: 2018. 05.03.
(*) Company; Patent: TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.01.
Cardio.>Arrhytmia. Atrial Fibrillation NonValvular AF (U)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Apixaban Tablets.
Oral Factor Xa Inhibitor AntiCoagulant.
EU Approval Date: 2012. 11.20.
USA Approval Date: 2013. 02.01.
(*) Companies; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.29.
Cardio.>Arrhytmia. Atrial Fibrillation NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant
EU Approval Date : ?
USA Approval Date: 2010. 10.19.
Patent No. 01 Expiration Date: 2018. 02.18.
(*) Company; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.30.
Cardio.>Arrhytmia. Atrial Fibrillation NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant. REVERSAL: IdarucizuMAb
IV Injection 5 g.
USA Approval Date: 2015. 10.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.18.
Cardio.>Arrhytmia. Atrial Fibrillation
(AFi). NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk
Reduction:
Left Atrial Appendage (LAA) Closure De-
vice. (U>Ab.)
EU Approval Date: 2013. 01.18.
(*) Company; Patents & TradeMark Avai-
lable on Request
UpDate: 2019. 03.03.
Cardio.>Arrhytmia. Atrial Fibrillation
(AFi). NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk
Reduction:
Left Atrial Appendage (LAA) Closure De-
vice. (U>Bo.)
EU Approval Date : 2009.
USA Approval Date: 2015. 03.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.04.
Cardio.>Arrhytmia. Atrial Fibrillation NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Rivaroxaban Tablets.
Xa Inhibitor.
EU Approval Date : 2011. 12.19.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 02.04.
Cardio.>Arrhytmia. Atrial Fibrillation NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Warfarin Sodium Tablets.
(*) Company : Bristol Myers Squibb.
Patent : Expired
TradeMark: Coumadin
Web-Site : www.coumadin.bmscustomerconnect.com
UpDate: 2018. 02.02.
Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Treat.: Mapping & Ablation System Offering>
. Single-Shot Pulmonary Vein Isolation
. High Definition Mapping &
. Atrial RadioFrequency Ablation
All in Single Catheter.
EU CE Mark Date: 2020. 06.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.07.
Cardio.>Arrhytmia. Atrial Fibrillation Treat.: Quartz CF (Contact Force) Ablation Catheter SE (Sensor Enabled).
EU Approval Date : 2017. 05.09.
USA Approval Date: 2019. 01.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.28.
Cardio.>Arrhytmia. Atrial Fibrillation (AFi.) Treat.: RadioFrequency (RF) Abla- tion. Bipolar RF Clamps.
Persistent and Long-Standing Persistent
(Non-Paroxysmal) during Open-Heart Concomitant Coronary Artery Bypass Grafting (CABG) &/or Valve Replacement or Repair Procedures.
USA Approval Date: 2011. 12.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.
Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Treat.: Sotalol IV.>
>1-day Hospital Outpatient Initiation &
faster Dose Escalations for existing
patients
>Reducing Hospital costs and improving
patient satisfaction
>Shortens the Hospital stay from 3 days
to 1 day
USA Approval Date: 2020. 03.10.
(*) Company; Patent & Web-Sites Avai-
lable on Request.
UpDate: 2020. 03.15.
Cardio.>Atrial Fibrillation (AFi). AI Mapping Software.
EU CE Mark Date : ?
USA Approval Date: 2020. 12.09.
(*) Company; Patent; Product Name &
Web-Site Available on Request.
UpDate: 2021. 02.08.
Cardio.>Atrial Fibrillation (AFi). Detection. Mobile Telemetry Wearable Device.
USA Approval Date: 2019. 04.30.
USA Launch Date: 2021. 01.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.08.
Cardio.>Atrial Fibrillation (AFi).
Detection.
Physician Prescribed Wearable Watch-Like
Device.
USA Approval Date: 2020. 10.15.
(*) Companies; TradeMark; USA Patent
APPs. & Web-Site Available on
Request
UpDate: 2021. 02.07.
Cardio.>Atrial Fibrillation (AFi). Detection. Wearable Watch.
EU CE Mark Date : 2021. 02.10.
IL Approval Date: 2020. 08.06.
(*) Company; Patents & Web-Site Avai-
lable on request
UpDate: 2021. 02.11.
Cardio.>Atrial Fibrillation (AFi). Treat.: Endoscopic Laser Ablation Sys- tem.
EU Approval Date : 2019. 03.25.
USA Approval Date: 2020. 05.12.
USA Launch Date: 2020. 06.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 08.27.
Cardio.>Atrial Fibrillation (AFi). Treat.: Temperature Controled Irrigated RadioFrequency (RF) Ablation System with Diamonds.
EU Approval Date : 2017.
USA Approval Date: 2021. 01.29.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 02.08.
Cardio.>ElectroPhysiology Device. Description: The non-invasive System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures.
One of the most common reasons for an EP procedure is the diagnosis and treatment of atrial fibrillation. Atrial fibrilla- tion is the most common arrhythmia ..
USA Approval Date: 2018. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 06.04
Cardio.>Left Atrial Appendage (LAA) Closure Device.
In Arrhytmia>Atrial Fibrillation (AFi.)
Patients.
EU >Approved.
JP >Approved.
USA>Launched.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.
Cardio.>Left Atrial Appendage (LAA) Closure Device.
Stroke Risk Reduction in NonValvular
AFi Patients.
EU Approval Date: 2013. 01.18.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2019. 03.03.
Critical Care Medicine>Atrial Fibrilla-tion Conversion to Synus Rhythm>Verna-kalant.HCl Inj.
Non-Surgery Patients with AFi < 7 days
Post Cardiac Surgery Patients with AFi<
3 days.
CA Approval Date: 2017. 03.14.
CA Launch Date: 2018. 10.24.
EU Approval Date: 2010. 09.
(*) Companies; Patents; TradeMark &
Web-Sites Available on Request.
UpDate: 2021. 02.06.
Critical Care Medicine>Atrial Fibrilla- tion or Atrial Flutter in PeriOperative, PostOperative, or other Emergent situations.
Ventricular Rate Rapid Control: Esmolol HCl in Water for Injection. GENERIC.
USA Launch Date: 2018. 03.01.
(*) Company: WG Critical Care.
www.wgcriticalcare.com
UpDate: 2018. 03.02.
Recurrence. Retardation. Propafenone.HCl
ER Capsules. Brand.
USA Initial Approval Year: 1989.
(*) Company : GlaxoSmithKline.
Patent : Expired
TradeMark: RYTHMOL SR
Web-Site :
www.gsksource.com/rythmolsr
UpDate: 2019. 02.25.
Recurrence. Retardation. Propafenone.HCl
ER Capsules. Generic.
USA Launch Date: 2016. 06.02.
(*) Company: Mylan.
UpDate: 2019. 02.25.
Treat.: Dofetilide Capsules. Brand.
USA Approval Date: 1999. 10.01.
(*) Company : Pfizer.
Patent : Expired
TradeMark: TIKOSYN
Web-Site : www.tikosyn.com
UpDate: 2019. 03.17.
Treat.: Dofetilide Capsules. Generic.
USA Approval & Launch Date: 2016. 06.07.
(*) Company: Mayne Pharma.
UpDate: 2019. 02.26.
Treat.: Sotalol.HCl Tablets. Generic.
(*) Company: Mylan.
UpDate: 2019. 02.20.
>ATRIAL FIBRILLATION (AFi). *'s products
This section has no products